Pharmafile Logo

immersive

- PMLiVE

FDA rejects Provention Bio’s type 1 diabetes prevention drug

FDA said a study of healthy volunteers failed to demonstrate that the planned commercial product is comparable to an older version used in previous clinical trials

- PMLiVE

Breakthrough therapy designated for Lilly’s investigational Alzheimer’s drug donanemab

The BTD is based on data from the phase 2 TRAILBLAZER-ALZ study in early symptomatic Alzheimer's patients

Building Better Patient Advocates Through Authentic Partnerships

Sabrina Hanna, Founder & CIO of the Cancer Collaborative, discusses precision medicine, innovation in oncology, how to build better patient advocates, and the current gaps when it comes to patient-centricity...

Impetus Digital

Biogen Idec building

Biogen plans confirmatory trial as FDA documents show struggle over Aduhelm approval

Confirmatory trial is planned to be completed ahead of nine-year time frame

S Marchant (L) A Korving (C) D Youds (R)

RESONANT GROUP APPOINTS STEPHEN MARCHANT CHIEF DEVELOPMENT OFFICER

Stephen Marchant has joined Resonant Group in the newly created role of Chief Development Officer.  He will be working with the Board to create, grow and acquire businesses and services to...

Origins – The Patient Focused Specialists

- PMLiVE

FDA approves Biogen’s aducanumab for Alzheimer’s disease in ‘landmark’ decision

FDA is requiring Biogen to conduct a new randomised, controlled clinical trial to verify the drug’s clinical benefit for Alzheimer’s patients

- PMLiVE

Moderna seeks full FDA approval for its COVID-19 vaccine

Moderna's mRNA-based vaccine is currently authorised for emergency use in the US

- PMLiVE

BMS’ Zeposia gains FDA approval in ulcerative colitis

Treatment was initially approved in 2020 for multiple sclerosis

- PMLiVE

FDA panel backs Provention Bio’s type 1 prevention drug teplizumab

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) narrowly voted in favour of supporting approval of the drug

- PMLiVE

FDA priority review granted for J&J, Legend Biotech’s myeloma CAR T therapy

CAR T therapy demonstrated an overall response rate of 97% in relapsed/refractory multiple myeloma patients after 12.4 months

- PMLiVE

Origins Insights nominated for two EVCOM Clarion Awards

Origins Insights excited to have our 'What One Thing...?' RDD film shortlisted for two awards!

Origins – The Patient Focused Specialists

- PMLiVE

FDA approves Apellis’ Empaveli for rare blood disease

PEGASUS study results show Empaveli is better than Soliris at improving haemoglobin levels

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links